FIT screening

The FIT-based screening test is easy and therefore manages to attract high participation rates – the main driver behind the success of any national or regional screening programme. Generally, national or regional administrations assume responsibility for managing the logistics, financials and efficiency of the programme in close cooperation with their selected laboratory partners.

For further information, you can check our FIT for screening microsite. 
www.fitscreening.eu/

 

 

March - Anti-platelet drugs mechanism

Blood platelets are activated by collagen released at the site of a vascular injury, by the change of blood flow (shear stress) and by thrombin formation. Platelets also increase their own activation by two mechanisms: the release of ADP and the thromboxane A2generation (TXA2), a potent platelet agonist. These mechanisms are also anti-platelet drugs’ main pharmacological targets: ADP receptor antagonists (thienopyridines) blockplatelet ADP receptors (P2Y12). Aspirin blocks cyclooxygenase (COX1), responsible for generating thromboxane A2 (TXA2). Sysmex’s CS-series coagulation analysers (exceptCS-1600) monitor anti-platelet drugs by Revohem reagents (ADP, arachidonic acid).

Scientific Calendar 2017

Enjoy our Media Centre
All
  • All
  • Documents
  • Podcast
  • Images
  • Videos
SUSPECTED HUS IN ROUTINE ANALYSIS
See the Podcast